
TY  - JOUR
TI  - Abstracts
JO  - Haemophilia
JA  - Haemophilia
VL  - 26
IS  - S2
SN  - 1351-8216
UR  - https://doi.org/10.1111/hae.13911
DO  - doi:10.1111/hae.13911
SP  - 27
EP  - 181
PY  - 2020
ER  - 

TY  - JOUR
TI  - Abstracts from the American College of Clinical Pharmacy 2012 Virtual Poster Symposium, May 22–24, 2012
JO  - Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
JA  - Pharmacotherapy
VL  - 32
IS  - 5
SN  - 0277-0008
UR  - https://doi.org/10.1002/j.1875-9114.2011.01136.x
DO  - doi:10.1002/j.1875-9114.2011.01136.x
SP  - e108
EP  - e133
PY  - 2012
ER  - 

TY  - JOUR
TI  - Free Papers
JO  - Colorectal Disease
JA  - Colorectal Dis
VL  - 21
IS  - S3
SN  - 1462-8910
UR  - https://doi.org/10.1111/codi.14773
DO  - doi:10.1111/codi.14773
SP  - 6
EP  - 18
PY  - 2019
ER  - 

TY  - JOUR
TI  - Abstract
JO  - Journal of Thrombosis and Haemostasis
JA  - Journal of Thrombosis and Haemostasis
VL  - 5
IS  - S2
SN  - 1538-7933
UR  - https://doi.org/10.1111/j.1538-7836.2007.tb00020.x
DO  - doi:10.1111/j.1538-7836.2007.tb00020.x
SP  - P-M-501
EP  - P-M-701
PY  - 2007
ER  - 

TY  - JOUR
AU  - Hanson, Sheila J.
AU  - Havens, Peter L.
AU  - Simpson, Pippa M.
AU  - Nugent, Melodee L.
AU  - Wells, Robert G.
TI  - Intrapleural alteplase decreases parapneumonic effusion volume in children more than saline irrigation
JO  - Pediatric Pulmonology
JA  - Pediatr Pulmonol.
VL  - 50
IS  - 12
SN  - 8755-6863
UR  - https://doi.org/10.1002/ppul.23184
DO  - doi:10.1002/ppul.23184
SP  - 1328
EP  - 1335
KW  - fibrinolysis
KW  - empyema
KW  - pleural effusion
KW  - pediatric
PY  - 2015
AB  - Summary Objective In this prospective, double-blind, randomized crossover trial, we determined the effect of intrapleural fibrinolysis with alteplase compared to that of normal saline irrigation on the thoracostomy tube output and pleural effusion volume in children with complicated parapneumonic effusion. Methods Twenty seven children, median age 3.5 years, referred to the interventional radiology service for thoracostomy tube drainage of a parapneumonic effusion were studied. Seventeen patients with pleural fluid thickness greater than 2?cm or >20% ipsilateral chest volume after 8?hr of thoracostomy tube drainage entered the treatment arm. They were randomized to receive alteplase 0.1?mg/kg twice a day on days 1 and 3, or on days 2 and 4, with normal saline irrigation on the alternate days. Daily pleural fluid volume measured by low dose chest computed tomography (CT) and thoracostomy tube output was compared between the saline and alteplase groups. Results Compared to normal saline irrigation, alteplase irrigation resulted in increased thoracostomy tube drainage and to a greater decline in pleural fluid volume. Earlier alteplase administration resulted in increased fluid mobilization compared to administration later in the hospital course. There were no bleeding complications. Conclusions Intrapleural fibrinolysis with alteplase safely increases pleural drainage and decreases the volume of pleural inflammatory debris compared to intrapleural administration of normal saline. The benefit of intrapleural alteplase on decreasing the volume of pleural inflammatory debris occurs for up to 72?hr with repeated twice daily dosing. Pediatr Pulmonol. 2015; 50:1328?1335. ? 2015 Wiley Periodicals, Inc.
ER  - 

TY  - JOUR
AU  - Alangaden, George J
AU  - Thyagarajan, Rama
AU  - Gruber, Scott A.
AU  - Morawski, Katherina
AU  - Garnick, James
AU  - El-Amm, Jose M.
AU  - West, Miguel S.
AU  - Sillix, Dale H.
AU  - Chandrasekar, Pranatharthi H.
AU  - Haririan, Abdolreza
TI  - Infectious complications after kidney transplantation: current epidemiology and associated risk factors
JO  - Clinical Transplantation
VL  - 20
IS  - 4
SN  - 0902-0063
UR  - https://doi.org/10.1111/j.1399-0012.2006.00519.x
DO  - doi:10.1111/j.1399-0012.2006.00519.x
SP  - 401
EP  - 409
KW  - African-American
KW  - immunosuppression
KW  - infection
KW  - kidney transplantation
PY  - 2006
AB  - Abstract:? Background:? The impact of newer immunosuppressive and antimicrobial prophylactic agents on the pattern of infectious complications following kidney transplantation has not been well studied. Methods:? This is an observational study in 127 adult recipients transplanted from 2001 to 2004. Patients received thymoglobulin (ATG) (50%) or basiliximab (50%) for induction and were maintained on mycophenolate mofetil, either tacrolimus (73%) or sirolimus (SRL) (27%), and prednisone (79%). Antimicrobial prophylaxis included perioperative cefazolin, trimethoprim/sulfamethaxazole for six?months, valganciclovir for three?months and nystatin for two?months. Regression models were used to examine the association of various factors with infections. Results:? We observed 127 infections in 65 patients, consisting of urinary tract infection (UTI) (47%), viral infections (17%), pneumonia (8%) and surgical wound infections (7%). UTI was the most common infection in all post-transplant periods. Enterococcus spp. (33%) and Escherichia coli (21%) were the most prevalent uropathogens. Of six patients with cytomegalovirus infection, none had tissue-invasive disease. There were no cases of pneumocystis pneumonia or BK nephropathy. Six patients developed fungal infections. Two deaths due to disseminated Rhizopus and Candida albicans accounted for a 1.5% infection-related mortality. Retransplantation and ureteral stents were independently associated with UTI (OR?=?4.5 and 2.9, p?=?0.06 and 0.03, respectively), as were ATG and SRL with bacterial infections (OR?=?3.3 and 2.5, p?=?0.009 and 0.047, respectively). Conclusion:? This study suggests that the use of newer immunosuppressive agents in recent years is associated with some changes in the epidemiology of post-transplant infections. Enterococci have become the predominant uropathogen. Invasive fungal infections, although rare, are often fatal.
ER  - 

TY  - JOUR
TI  - ICA 2013 Congress Poster Abstracts
JO  - Andrology
JA  - Andrology
VL  - 1
IS  - s1
SN  - 2047-2919
UR  - https://doi.org/10.1111/j.2047-2927.2012.00065.x
DO  - doi:10.1111/j.2047-2927.2012.00065.x
SP  - 44
EP  - 114
PY  - 2013
ER  - 

TY  - JOUR
TI  - ANA T1–T136
JO  - Annals of Neurology
JA  - Ann Neurol.
VL  - 62
IS  - S11
SN  - 0364-5134
UR  - https://doi.org/10.1002/ana.11641
DO  - doi:10.1002/ana.11641
SP  - S50
EP  - S83
PY  - 2007
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Journal of Inherited Metabolic Disease
JA  - J Inherit Metab Dis
VL  - 42
IS  - S1
SN  - 0141-8955
UR  - https://doi.org/10.1002/jimd.12153
DO  - doi:10.1002/jimd.12153
SP  - 1
EP  - 479
PY  - 2019
ER  - 

TY  - JOUR
TI  - 12Th Clinical Congress Abstracts Short Paper Sessions
JO  - Journal of Parenteral and Enteral Nutrition
JA  - Journal of Parenteral and Enteral Nutrition
VL  - 12
IS  - 1S
SN  - 0148-6071
UR  - https://doi.org/10.1177/0148607188012001011
DO  - doi:10.1177/0148607188012001011
SP  - 3S
EP  - 24S
PY  - 1988
ER  - 

TY  - JOUR
TI  - Abstracts for Poster sessions
JO  - Cytometry
JA  - Cytometry
VL  - 8
IS  - S1
SN  - 0196-4763
UR  - https://doi.org/10.1002/cyto.990080704
DO  - doi:10.1002/cyto.990080704
SP  - 34
EP  - 104
PY  - 1987
ER  - 

TY  - JOUR
TI  - ACCP 1998 ANNUAL MEETING ABSTRACTS
JO  - Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
VL  - 18
IS  - 2
SN  - 0277-0008
UR  - https://doi.org/10.1002/j.1875-9114.1998.tb03874.x
DO  - doi:10.1002/j.1875-9114.1998.tb03874.x
SP  - 426
EP  - 447
PY  - 1998
ER  - 

TY  - JOUR
TI  - Poster Abstracts
JO  - Colorectal Disease
JA  - Colorectal Dis
VL  - 21
IS  - S3
SN  - 1462-8910
UR  - https://doi.org/10.1111/codi.14775
DO  - doi:10.1111/codi.14775
SP  - 33
EP  - 128
PY  - 2019
ER  - 

TY  - JOUR
TI  - Abstracts (Continue in Part I)
JO  - Proceedings of the International Society for Magnetic Resonance in Medicine
JA  - Proc. Soc. Magn. Reson. Med.
VL  - 1988
IS  - S3
SN  - 1065-9889
UR  - https://doi.org/10.1002/mrmp.22419880302
DO  - doi:10.1002/mrmp.22419880302
SP  - 1
EP  - 50
PY  - 1988
ER  - 

TY  - JOUR
TI  - Tuesday, 8 April
JO  - British Journal of Haematology
VL  - 121
IS  - s1
SN  - 0007-1048
UR  - https://doi.org/10.1046/j.1365-2141.121.s1.5.x
DO  - doi:10.1046/j.1365-2141.121.s1.5.x
SP  - 41
EP  - 86
PY  - 2003
ER  - 

TY  - JOUR
TI  - Orals
JO  - Transplant International
JA  - Transpl Int
VL  - 28
IS  - S4
SN  - 0934-0874
UR  - https://doi.org/10.1111/tri.12701
DO  - doi:10.1111/tri.12701
SP  - 134
EP  - 276
PY  - 2015
ER  - 

TY  - JOUR
TI  - Medical Topics
JO  - Haemophilia
VL  - 14
IS  - s2
SN  - 1351-8216
UR  - https://doi.org/10.1111/j.1365-2516.2008.01725.x
DO  - doi:10.1111/j.1365-2516.2008.01725.x
SP  - 1
EP  - 119
PY  - 2008
ER  - 

TY  - JOUR
AU  - Li, Zhaoyang
AU  - Gan, Liang-Shang
AU  - Marbury, Thomas
AU  - Lasseter, Kenneth C.
AU  - Natarajan, Amy
AU  - Stecher, Scott
AU  - Wei, Dong
AU  - Yang, Liyu
AU  - Freedman, Daniel
AU  - Deykin, Aaron
TI  - Pharmacokinetics of Oral Tonapofylline and Its Acyl-Glucuronide Metabolite in Patients With Mild and Moderate Hepatic Impairment
JO  - The Journal of Clinical Pharmacology
VL  - 52
IS  - 4
SN  - 0091-2700
UR  - https://doi.org/10.1177/0091270011400413
DO  - doi:10.1177/0091270011400413
SP  - 543
EP  - 551
KW  - Pharmacokinetics
KW  - hepatic impairment
KW  - tonapofylline
KW  - acyl-glucuronide
KW  - metabolite
PY  - 2012
AB  - The objective of the study was to evaluate the effect of hepatic impairment on the pharmacokinetics of tonapofylline. Patients with mild or moderate hepatic impairment were enrolled in parallel with demographically matched healthy subjects. All study participants received a single 75-mg oral tonapofylline capsule. The pharmacokinetic parameters for both tonapofylline and its active metabolite, acyl-glucuronide (tonapofylline-AG), were affected by hepatic impairment significantly (P < .1) except for time to peak plasma concentration (tmax), terminal half-life (t1/2), and apparent volume of distribution based on the terminal phase (Vdz/F). In the mild group, peak plasma concentration (Cmax), area under the time-concentration curve from time 0 to 48 hours postdose (AUC48h), and from time 0 to infinity (AUCinf) of tonapofylline modestly increased as compared with the control healthy subjects (GMR 1.62, 1.57, and 1.53, respectively). The extent of increase of these parameters for tonapofylline-AG was more profound than tonapofylline with geometric mean ratio (GMR) ranging from 2.02 to 2.08. Moderate hepatic impairment was also associated with modest increases of Cmax, AUC48h, and AUCinf of tonapofylline (GMR 1.41, 1.98, and 2.08, respectively). Similar to the mild group, the increase of these parameters were higher for tonapofylline-AG with GMR ranging from 2.80 to 3.86. Single oral 75-mg tonapofylline was safe and well tolerated in patients with mild or moderate hepatic impairment.
ER  - 

TY  - JOUR
TI  - 2014 Annual Meeting of the American Society for Bone and Mineral Research Houston, TX September 12–15, 2014
JO  - Journal of Bone and Mineral Research
JA  - J Bone Miner Res
VL  - 29
IS  - S1
SN  - 0884-0431
UR  - https://doi.org/10.1002/jbmr.2476
DO  - doi:10.1002/jbmr.2476
SP  - S1
EP  - S1
PY  - 2014
AB  - ABSTRACT Searchable abstracts may be found at http://www.asbmr.org/education/abstracts
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Hepatology
JA  - Hepatology
VL  - 54
IS  - S1
SN  - 0270-9139
UR  - https://doi.org/10.1002/hep.24666
DO  - doi:10.1002/hep.24666
SP  - 360A
EP  - 1455A
PY  - 2011
ER  - 
